barzolvolimab

Monoclonal antibody

Partialsignal

Evidence outlook · lead readout

EMBARQ-CSU1 (NCT06445023) · Chronic Spontaneous Urticaria

The completed lead evidence is positive, with design limits that temper confidence; the rationale below says which.

EMBARQ-CSU1 (NCT06445023): This was a randomized, double-blind, placebo-controlled Phase 3 in chronic spontaneous urticaria. Its primary endpoint, UAS7 change at week 12, is a validated clinical scale and was met according to the company's topline release. The sources read give no power calculation, so the grade is moderate.

Also in development:Atopic Dermatitis · Phase 2Chronic Inducible Urticaria · Phase 3

Development in Eosinophilic Esophagitis stopped (2025-08) after a negative readout. Source

Development in Prurigo Nodularis stopped (2026-07) after a negative readout. Source

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (4)
Chronic Inducible Urticaria
Chronic Spontaneous Urticaria
NCT07256392 · Celldex Therapeutics
2025-11-25 – 2028-09 · Chronic Spontaneous Urticaria
What this study did
Phase 2 (5)
Atopic Dermatitis
Chronic Inducible Urticaria
NCT05405660 · Celldex Therapeutics
2022-06-28 – 2025-09-12 · Chronic Inducible Urticaria
What this study did
Chronic Spontaneous Urticaria
NCT05368285 · Celldex Therapeutics
2022-05-19 – 2024-12-20 · Chronic Spontaneous Urticaria
What this study did
Other / comorbidity
NCT06366750 · Celldex Therapeutics
2024-04-12 – 2027-03 · Prurigo Nodularis
What this study did
NCT05774184 · Celldex Therapeutics
2023-06-01 – 2026-01-23 · Eosinophilic Esophagitis
What this study did
Phase 1 (5)
Chronic Spontaneous Urticaria
NCT04538794 · Celldex Therapeutics
2020-09-24 – 2023-01-17 · Chronic Spontaneous Urticaria
What this study did
Other / comorbidity
NCT04944862 · Celldex Therapeutics
2021-11-08 – 2023-07-31 · Prurigo Nodularis
What this study did
NCT04548869 · Celldex Therapeutics
2020-11-24 – 2023-05-12 · Cold Urticaria, Cold Contact Urticaria, Symptomatic Dermographism, Symptomatic Dermatographism, Cholinergic Urticaria
What this study did
NCT05031624 · Celldex Therapeutics
2021-08-30 – 2022-01-14 · Healthy Subjects
What this study did
NCT04146129 · Celldex Therapeutics
2019-10-29 – 2020-06-26 · Healthy Subjects
What this study did

Competitive landscape

4 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Chronic Spontaneous Urticaria: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Barzolvolimab: this drugPhase 3Monoclonal antibodyKITPartial signal
NCT06445023: Primary endpoint met: mean change from baseline in weekly urticaria activity score (UAS7) at Week 12 vs placebo; all key secondary endpoints also met (Celldex, 2026-09-22).
NCT06455202: Primary endpoint met: mean change from baseline in weekly urticaria activity score (UAS7) at Week 12 vs placebo; all key secondary endpoints also met (Celldex, 2026-09-22).
Dupilumab (Dupixent)ApprovedMonoclonal antibodyIL-4R-alphanot yet gradedNo reviewed efficacy summary in this indication
Omalizumab (Xolair)ApprovedMonoclonal antibodyIgE (immunoglobulin E), IgEPartial signal
NCT01287117: Change From Baseline to Week 12 in the Weekly Itch Severity Score (Baseline to Week 12): Placebo -3.63 Units on a scale (Standard Deviation 5.22) | Omalizumab 75 mg -6.46 Units on a scale (Standard Deviation 6.14) | Omalizumab 150 mg -6.66 Units on a scale (Standard Deviation 6.28) | Omalizumab 300 mg -9.4 Units on a scale (Standard Deviation 5.73)
NCT01292473: Change in weekly itch severity score at week 12 vs placebo (-5.14): omalizumab 75 mg -5.87, difference -0.69 (95% CI -2.54 to 1.16), p=0.4637; 150 mg -8.14, difference -3.04 (95% CI -4.85 to -1.24), p=0.0011; 300 mg -9.77, difference -4.81 (95% CI -6.49 to -3.13), p<0.0001 (CT.gov posted results).
RemibrutinibApprovedSmall moleculeBruton's tyrosine kinase (BTK)Reliable signalNo reviewed efficacy summary in this indication
Bezuclastinib
Phase 3(overall)
Small moleculeKIT
not yet graded(overall)
No reviewed efficacy summary in this indication
Velzatinib
Phase 3(overall)
Small moleculeKIT
not yet graded(overall)
No reviewed efficacy summary in this indication
AK139Phase 2Multispecific antibodyIL-4 receptor alpha / ST2not yet gradedNo reviewed efficacy summary in this indication
CM512Phase 2Multispecific antibodyTSLP + IL-13not yet gradedNo reviewed efficacy summary in this indication
HRS-3095Phase 2Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
BriquilimabPhase 1/2Monoclonal antibodyKITnot yet gradedNo reviewed efficacy summary in this indication
Girocitinib
—(overall)
Small moleculeTYK2/JAK1Reliable signalNo reviewed efficacy summary in this indication
SAR449028
—(overall)
UndisclosedKITnot yet gradedNo reviewed efficacy summary in this indication
SHR-3095
—(overall)
Undisclosed—not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow barzolvolimab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (2)
June 2028 (1)
Phase 3Chronic Inducible UrticariaRecruiting
Est. primary completion 2028-06 · NCT07266402 · CT.gov ↗
What to watch
September 2028 (1)
Phase 3Chronic Spontaneous UrticariaEnrolling by invitation
Est. primary completion 2028-09 · NCT07256392 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

22 September 2026Topline resultBarzolvolimab Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 topline: primary and all key secondary endpoints met
Celldex Therapeutics · Source ↗
July 2026Topline resultPhase 2 in prurigo nodularis did not meet its primary or key secondary endpoints